Based on these results, we propose that anti-LAG3 may effectively overcome immunosuppression in the tumor microenvironment and be used, alone or in combination with other immune therapies such as MM-specific vaccination, to enhance generation and maintenance of antigen-specific memory CTL function against tumor. This evidence concerns the gene LAG3 and neoplasm.